The Oral GLP-1 Wave Is Coming — Adherence Is Still the Real Challenge
Oral semaglutide and orforglipron remove the needle and widen access to GLP-1s. But the central challenge — keeping patients on treatment past the first year — hasn't gone anywhere.
For a lot of people, injections are terrifying. A source of anxiety that brings you back to one of the less pleasant parts of childhood. The waiting room, the imminent jab of the needle. Rarely did the post injection sticker or lollipop actually seem like fair compensation for the ordeal. That’s why many think that Oral GLP-1 will get even more people starting their weight loss journey as starting on a pill rather than a jab is much more palatable. But whether more people start or not, the real challenge with GLPs hasn’t changed and that is keeping people on them.
The next wave of GLP-1 treatment is oral
The next wave of GLP-1 treatment sees the beginning of the transition from injections. Pills are rightly heralded as a removal of a significant barrier to GLP-1s. Oral semaglutide is already in patients’ hands and Eli Lilly’s orforglipron (the first small-molecule GLP-1 to clear Phase 3), is moving toward regulators worldwide. This comes off the back of trials showing mean weight loss of around 11% at 72 weeks. A once-daily pill with no needle removes one of the biggest reasons people never begin: the fear of injecting.
Wider access is good news — but it isn’t the problem
Consumption is about to rise considerably as access widens. That is genuinely good news but it doesn’t actually get to the source of the problem with GLP-1 usage. The central issues with GLP-1s is one of adherence. Having swathes of people try it and then give up in the short term doesn’t capture the long term benefits.
Most patients stop within the first year
The data indicates that a large share of patients stop within the first year. One large nationwide study of adults taking semaglutide for weight management found 18% had stopped by three months, 31% by six months and 42% by twelve. In cohorts of people without diabetes, first-year discontinuation has been measured above half. The adherence pattern is consistent across studies. A significant proportion of people who start GLP-1 therapy are no longer taking it a year later, and consequently, most of the clinical benefit leaves with them.
Why patients stop
The reasons for discontinuation are well understood. Gastrointestinal side effects, nausea, vomiting and diarrhoea, are the most common reason people give for stopping, and they cluster in the first weeks while the dosage is still being calibrated. One study demonstrated that a single moderate or severe GI episode raised the likelihood of stopping over the following year by roughly a fifth to a third. For people using these medicines for weight rather than diabetes, the tolerance threshold for side effects is even lower. Ultimately, the symptoms are real, the early results feel slow, and the support wrapped around them is usually lacking. This triad of issues make the lack of adherence seen in GLP-1 usage understandable.
Oral formulations don’t remove the problem — they reshape it
Oral formulations do not remove that problem. They reshape it. A weekly injection is a decision someone makes 52 times a year. A daily tablet is a decision they make 365 times, and oral semaglutide asks a lot of each one. It has to be taken on an empty stomach, with no more than 120 ml of water and at least 30 minutes before the first food, drink or other medicine of the day. Only around 1% of the dose is absorbed, so the routine is mandatory and getting it wrong limits efficacy. Layer the side effects of titration on top of a demanding daily ritual and you have more moments, every single day, where the thought of continuing treatment feels like just too much.
Orforglipron eases part of these issues with the pill. As a small molecule it is designed to be taken once daily without the fasting-and-water rules that constrain oral semaglutide. That is a tangible fix and it shows that the pharmacology element of pill use is being solved. Efficacy and convenience are converging fast but does this actually move the needle as it were on adherence?
Continuation is a support problem, not a pharmacology one
This is the uncomfortable truth of the oral era. Continuation is no longer a pharmacology problem. It is a behaviour and support problem. And this problem is not only a clinical concern it is also a commercial one. For the provider who dispenses and supports the medication, a patient who stops at month three is a worse outcome and a fraction of the lifetime value of one who reaches month twelve. For the health system, discontinuation is wasted spend and lost benefit. For everyone trying to understand how these medicines perform outside a trial, the people who drop out are precisely the data you never capture. The gap between the trial result and the actual patient result is, mostly, the gap in support between them.
Closing the gap
Closing that gap requires meeting the patient in the days between appointments: when the nausea hits, when they wonder whether a symptom is normal, when the daily routine is easy to skip and no one is watching. It requires education timed to where someone is in their treatment, not a leaflet handed over on day one. It requires a way for patients to track how they feel and bring that back to the clinician responsible for their care. Support in the GLP-1 weight loss journey is needed and it is exactly the layer most GLP-1 pathways are missing.
Where Cadence fits
This is the problem Cadence Health was built around. Cadence is a clinically grounded support platform for GLP-1 patients: daily, medication-aware content mapped to each person’s stage of treatment, symptom tracking patients can share with their clinician, and support Q&A for the questions that surface between appointments. Patients experience it as an app called nudge; partners get stronger adherence, higher patient lifetime value, and a real-world evidence layer a paper pathway can never produce. It stays firmly in its lane as an MHRA Class I information and behaviour-support tool: it never changes a dose and never makes a clinical decision. If you prescribe or dispense GLP-1 medication and first-year drop-off is your problem too, that is a conversation worth having.
Are you ready for the next wave of oral patients? Get in touch with the Cadence Health team for a consultation on how we can improve adherence in your GLP-1 patients.